In another approach, Hexagonal selenium nanoparticles modified by siRNA (HSNM-siRNA) were administered to NSCLC cells to inhibit Epidermal Growth Factor Receptor (EGFR/HER1/ErbB1) signaling and the intracellular accumulation of several TFs (NF-κΒ, c-MYC, STATs, and ELK1) was assessed [46]. The gene discussed is ELK1; the disease is non-small cell lung carcinoma.